Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy

by Juan Lopez, Benzinga Staff Writer

December 15, 2011 5:57 AM | 11 seconds read | Make a Comment

Goldman Sachs has upgraded Onyx Pharmaceuticals

ONXX

from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.

Posted In: Upgrades Price Target Pre-Market Outlook Analyst Ratings Americas Conviction Buy List Goldman Sachs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.